OBJECTIVE: It has been proposed that delayed ischemic neurological deficits are induced by red blood cell (RBC) products after subarachnoid hemorrhage. Prophylactic treatment with the Ca2+ antagonist nimodipine or prevention of systemic volume contraction reduces the occurrence of delayed ischemic neurological deficits. To gain insight into the underlying mechanism, we studied the effects of nimodipine or volume expansion on ischemic events induced by RBC products in rats. METHODS: A cranial window was implanted in 52 rats. At the window, cerebral blood flow (measured with laser Doppler flowmetry) and the subarachnoid direct current potential were recorded; the cortical surface was superfused with artificial cerebrospinal fluid. A spreading neuronal/astroglial depolarization wave was triggered at a remote site, from which it traveled to the cranial window. RESULTS: In 16 rats, the depolarization wave triggered an ischemic event at the cranial window when artificial cerebrospinal fluid containing the RBC product hemoglobin and elevated K+ levels was superfused. In contrast, in animals receiving intravenously administered nimodipine (n = 12) or moderate volume expansion/hemodilution with hydroxyethyl starch (6% hydroxyethyl starch 200/0.5) (n = 10), the depolarization wave triggered brief initial hypoperfusion, followed by brief hyperemia, in the cortical area exposed to the RBC products. Under physiological conditions, the depolarization wave triggered brief hyperemia (n = 14). CONCLUSION: Spreading ischemia induced by RBC products is antagonized by measures known to be beneficial in the prophylaxis of delayed ischemic neurological deficits. Our findings suggest that a mechanism involving the cortical microcirculation might underlie the therapeutic effects of nimodipine and volume expansion.
OBJECTIVE: It has been proposed that delayed ischemic neurological deficits are induced by red blood cell (RBC) products after subarachnoid hemorrhage. Prophylactic treatment with the Ca2+ antagonist nimodipine or prevention of systemic volume contraction reduces the occurrence of delayed ischemic neurological deficits. To gain insight into the underlying mechanism, we studied the effects of nimodipine or volume expansion on ischemic events induced by RBC products in rats. METHODS: A cranial window was implanted in 52 rats. At the window, cerebral blood flow (measured with laser Doppler flowmetry) and the subarachnoid direct current potential were recorded; the cortical surface was superfused with artificial cerebrospinal fluid. A spreading neuronal/astroglial depolarization wave was triggered at a remote site, from which it traveled to the cranial window. RESULTS: In 16 rats, the depolarization wave triggered an ischemic event at the cranial window when artificial cerebrospinal fluid containing the RBC product hemoglobin and elevated K+ levels was superfused. In contrast, in animals receiving intravenously administered nimodipine (n = 12) or moderate volume expansion/hemodilution with hydroxyethyl starch (6% hydroxyethyl starch 200/0.5) (n = 10), the depolarization wave triggered brief initial hypoperfusion, followed by brief hyperemia, in the cortical area exposed to the RBC products. Under physiological conditions, the depolarization wave triggered brief hyperemia (n = 14). CONCLUSION: Spreading ischemia induced by RBC products is antagonized by measures known to be beneficial in the prophylaxis of delayed ischemic neurological deficits. Our findings suggest that a mechanism involving the cortical microcirculation might underlie the therapeutic effects of nimodipine and volume expansion.
Authors: Johannes Woitzik; Jens P Dreier; Nils Hecht; Ingo Fiss; Nora Sandow; Sebastian Major; Maren Winkler; Yuliya A Dahlem; Jerome Manville; Michael Diepers; Elke Muench; Hidetoshi Kasuya; Peter Schmiedek; Peter Vajkoczy Journal: J Cereb Blood Flow Metab Date: 2011-12-07 Impact factor: 6.200
Authors: Martin Lauritzen; Jens Peter Dreier; Martin Fabricius; Jed A Hartings; Rudolf Graf; Anthony John Strong Journal: J Cereb Blood Flow Metab Date: 2010-11-03 Impact factor: 6.200
Authors: Robert F James; Daniel R Kramer; Zaid S Aljuboori; Gunjan Parikh; Shawn W Adams; Jessica C Eaton; Hussam Abou Al-Shaar; Neeraj Badjatia; William J Mack; J Marc Simard Journal: Curr Treat Options Neurol Date: 2016-08 Impact factor: 3.598
Authors: Jed A Hartings; C William Shuttleworth; Sergei A Kirov; Cenk Ayata; Jason M Hinzman; Brandon Foreman; R David Andrew; Martyn G Boutelle; K C Brennan; Andrew P Carlson; Markus A Dahlem; Christoph Drenckhahn; Christian Dohmen; Martin Fabricius; Eszter Farkas; Delphine Feuerstein; Rudolf Graf; Raimund Helbok; Martin Lauritzen; Sebastian Major; Ana I Oliveira-Ferreira; Frank Richter; Eric S Rosenthal; Oliver W Sakowitz; Renán Sánchez-Porras; Edgar Santos; Michael Schöll; Anthony J Strong; Anja Urbach; M Brandon Westover; Maren Kl Winkler; Otto W Witte; Johannes Woitzik; Jens P Dreier Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200
Authors: R Loch Macdonald; Blessing Jaja; Michael D Cusimano; Nima Etminan; Daniel Hanggi; David Hasan; Don Ilodigwe; Hector Lantigua; Peter Le Roux; Benjamin Lo; Ada Louffat-Olivares; Stephan Mayer; Andrew Molyneux; Audrey Quinn; Tom A Schweizer; Thomas Schenk; Julian Spears; Michael Todd; James Torner; Mervyn D I Vergouwen; George K C Wong; Jeff Singh Journal: Transl Stroke Res Date: 2013-01-07 Impact factor: 6.829
Authors: Inna Sukhotinsky; Mohammad A Yaseen; Sava Sakadzić; Svetlana Ruvinskaya; John R Sims; David A Boas; Michael A Moskowitz; Cenk Ayata Journal: J Cereb Blood Flow Metab Date: 2010-01-20 Impact factor: 6.200